Articles tagged with: Lenalidomide
NewsFlash »
Celgene Seeks Expanded Approval For Revlimid In Europe – The pharmaceutical company Celgene announced on Tuesday that it is seeking expanded approval for Revlimid (lenalidomide) as treatment for multiple myeloma in Europe. The European Medicines Agency (EMA) will review approval of Revlimid for maintenance therapy of newly diagnosed myeloma patients who have not progressed after initial therapy with melphalan (Alkeran), prednisone, and Revlimid or after autologous stem cell transplantation. Currently, Revlimid is approved in combination with dexamethasone for the treatment of patients who have received at least one prior therapy. For more information, please see the Celgene press release.
ENMD-2076 Is Safe In Relapsed/Refractory Multiple Myeloma (ASH 2010) – The investigational drug ENMD-2076, which is being developed by the pharmaceutical company EntreMed, is safe in relapsed / refractory multiple myeloma patients, according to the interim Phase 1 trial results presented at the 2010 Meeting of the American Society of Hematology (ASH). Researchers tested four different dose levels (150 mg to 400 mg) in 28-day cycles. They observed progression of disease for all patients receiving the minimum dose of 150 mg. Patients receiving a dose of 300 mg achieved stable disease with reductions in serum M-protein. Researchers did not observe any dose-limiting side effects. Most side effects were mild to moderate and included nausea, diarrhea, and fatigue. The optimal dosage has not yet been determined as the trial is still ongoing. For more information, please see abstract 1957 on the ASH annual meeting website and the clinical trial description.
Daratumumab Emerges As Potential Treatment In CD38-Positive Multiple Myeloma – Preclinical results showed that the experimental drug daratumumab is highly effective at killing cancerous cells that produce the CD38 molecule. The Danish biotechnology company Genmab is currently developing daratumumab for treatment of CD38-positive multiple myeloma tumors. Researchers initially tested a broad array of CD38 antibodies against more than 10 primary tumors from myeloma patients, and daratumumab was found to be the most effective at executing the immune system killing mechanisms. Genmab is currently conducting a Phase 1/2 study to determine the safety and optimal dosage of daratumumab. For more information, please see the study in the Journal of Immunology (abstract) and the clinical trial description.
PBOX-15 Induces Cell Death In Multiple Myeloma Cells – Preclinical results demonstrated that the experimental drug compound PBOX-15 (1,5-benzoxazepine-15), discovered by Irish clinical scientists, is a promising treatment for multiple myeloma. Researchers found that PBOX-15 induced cell death in four different lines of multiple myeloma cells. In two of the cell lines, PBOX-15 increased the number of death receptor genes to stimulate cell death. For more information, please see the study in the British Journal of Cancer (abstract).
News»
Results of a Phase 1 clinical trial suggest that the cancer drug Treanda, in combination with Revlimid and dexamethasone, is highly active and well tolerated in relapsed and refractory multiple myeloma patients.
Dr. Suzanne Lentzsch, of the University of Pittsburgh School of Medicine and Cancer Institute, presented the results of the study at the American Society of Hematology (ASH) 2010 annual meeting in Orlando.
Based on the safety of the Treanda, Revlimid, dexamethasone regimen observed in this study, Dr. Lentzsch believes that this combination may be particularly well suited for older patients …
News»
The results of a number of clinical trials for the treatment of multiple myeloma with Zolinza were presented at the American Society of Hematology (ASH) 2010 annual meeting. The trials, ranging from Phase 1 to Phase 3, studied Zolinza in combination with a variety of approved myeloma drugs for the treatment of both early and advanced stages of the disease.
Zolinza (vorinostat) is manufactured by Merck Pharmaceuticals. It is currently approved for a certain type of lymphoma and is being investigated as a treatment for multiple myeloma (see related Beacon …
News»
Carfilzomib is well tolerated and highly active in both newly diagnosed multiple myeloma patients as well as relapsed and treatment-resistant patients, according to the results of two recent clinical trials that were presented at the American Society of Hematology 2010 annual meeting in Orlando earlier this month.
These results further underscore carfilzomib’s activity in multiple myeloma. Several studies with promising results were also reported in poster sessions during the annual meeting (see related Beacon news).
Like Velcade (bortezomib), carfilzomib (Kyprolis), which is being developed by Onyx Pharmaceuticals, is a …
News»
Patients under age 65 who undergo autologous stem cell transplantation early have significantly higher survival rates than patients who receive continued treatment with Revlimid and dexamethasone, according to a retrospective analysis of a recent clinical trial.
However, Dr. David Siegel, from the Hackensack University Medical Center in New Jersey and lead investigator of the study, pointed out that these results need to be interpreted cautiously, because the patients were not randomly selected to receive either an early or late stem cell transplant.
The results do suggest, however, that early transplantation may be …
News»
The results of three ongoing clinical trials suggest that elotuzumab in combination with either Velcade (bortezomib) or Revlimid (lenalidomide) plus low-dose dexamethasone (Decadron) is effective and well-tolerated in patients who have relapsed or have treatment-resistant multiple myeloma.
The findings were presented at the American Society of Hematology (ASH) annual meeting in Orlando last week.
Elotuzumab is a new drug being developed by Facet Biotech and Bristol-Myers Squibb as a potential treatment for multiple myeloma. It recognizes and binds to unique proteins on the surface …
News»
Three studies presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando support the use of Revlimid as maintenance therapy for multiple myeloma patients.
In two studies, Revlimid (lenalidomide) maintenance increased time to disease progression among multiple myeloma patients after stem cell transplantation.
A third study showed the same benefit for older newly diagnosed multiple myeloma patients who are not candidates for stem cell transplantation.
Side effects were minor across all three studies. However, the researchers did observe the occurrence of secondary cancers in a small …